Real‐world outcomes of cisplatin, capecitabine, and gemcitabine with either epirubicin (PEXG) or docetaxel (PDXG) as first‐line palliative treatment in metastatic or unresectable locally advanced pancreatic adenocarcinoma.
Saved in:
| Title: | Real‐world outcomes of cisplatin, capecitabine, and gemcitabine with either epirubicin (PEXG) or docetaxel (PDXG) as first‐line palliative treatment in metastatic or unresectable locally advanced pancreatic adenocarcinoma. |
|---|---|
| Authors: | Hitchen, Nadia1,2 (AUTHOR) NHitchen@adhb.govt.nz, Waldron, Nick R.1 (AUTHOR), Deva, Sanjeev1,2 (AUTHOR), Findlay, Michael1,2 (AUTHOR), Lawrence, Benjamin1,2 (AUTHOR) |
| Source: | Asia Pacific Journal of Clinical Oncology. Oct2023, Vol. 19 Issue 5, pe231-e238. 8p. |
| Database: | Academic Search Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 17437555 |
|---|---|
| DOI: | 10.1111/ajco.13845 |
